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The recent failures of the solanezumab Expedition 3 and the verubecestat phase 
II/III trials to significantly slow disease progression in mild or mild to moderate 
Alzheimer’s disease are considerable disappointments. They are causing soul 
searching in the field: are we on the right track and what do we need to do to get 
effective mechanistic therapies?  While there have been previous trial failures of 
anti-amyloid therapies, most of these had clear problems during their preclinical 
development, which perhaps should have allowed their failure to be foreseen 
(Karran and Hardy 2014).  The solanezumab trial, in contrast, had been 
approached with cautious optimism in the light of the marginally positive data 
on clinical slowing in mild disease in secondary analyses of the earlier 
Expedition and Expedition 2 trials (Doody et al. 2014). Verubecestat appeared to 
be a safe and effective BACE-1 inhibitor (Kennedy et al. 2016) allowing effective 
Aβ lowering in the central nervous system.  Thus both approaches appeared to 
have overcome most of the shortcomings encountered in previous trials 
although the fact that biomarker confirmation of Alzheimer pathology was not 
required in the verubecestat trial was a clear shortcoming.  In addition the two 
approaches are complementary as they hit the Aβ peptide from either the 
clearance side (solanezumab) or from the production side (verubecestat). Thus, 
these were two serious tests of the amyloid hypothesis, and, in practical clinical 
terms, both turned out negative.   
With the repetitive failing of trials, it is time to reconsider the 25 year old 
amyloid cascade hypothesis (Selkoe and Hardy, 2016) and the clinical equivalent 
data summarized in the “Jack curves” (Jack and Holtzman 2013). Both imply a 
linear relationship between the occurrence of Aβ pathology and neuronal cell 
death and dementia. Dementia is however the clinical manifestation of a much 
more complex process not only involving neurons, but also strong other cellular 
reactions from microglia, astroglia, oligodendrocytes and vasculature. Dementia 
may not be a direct consequence of Aβ toxicity but instead as the result of a 
decade long disease process called the “cellular phase” of Alzheimer’s Disease 
(De Strooper and Karran. 2016).  Genetic evidence for this complexity comes 
from the identification of microglial response genes as risk loci for Alzheimer’s 
disease (Matarin et al. 2015) 
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At a theoretical level, the negative outcome of anti-amyloid therapy was not 
excluded, even without putting the causal contribution of Aβ to AD into question 
(Karran et al. 2011).  In one disease scenario, Aβ was proposed as a driver of the 
disease process.  If this would be the case, any lowering of Aβ would slow disease 
progression. This possibility is ruled out by the failed clinical trials. In another 
scenario (Karran et al, 2011), Aβ has to reach a certain threshold to cause harm. 
If Aβ therapy is not able to lower the Aβ level in the brain below that threshold, 
then no beneficial effects of anti-amyloid drugs would be expected.  In the third 
scenario, Aβ is proposed to be only a trigger of the disease process (Karran et al. , 
2011). If this is the case, then Aβ directed drugs would have no effect at all after 
the disease process has been initiated. It looks like the failed trials are consistent 
with both the threshold and the trigger scenarios. The alternative possibility that 
Aβ is an entirely innocent bystander of the disease process is unlikely as it is not 
reconcilable with genetic evidence that mutations in APP are sufficient to cause 
Alzheimer disease.   
More detailed analysis of the solenezumab trial data is possible because they 
were made entirely available by Eli-Lilly.  ADAS-Cog scores showed tiny 
improvements, in the same direction as the trends in the earlier solanezumab 
trials (Siemers et al. 2016).  For example, in mild Alzheimer’s disease, the 
improvement in ADAS-Cog over 80 weeks on drug was 44% in Expedition, 20% 
in Expedition 2 but only 11% in Expedition 3 (p=0.095).  These data overall may 
suggest some small influence of Aβ lowering on disease progression. We have to 
wait until all data from the verubecestat trail are made available to see whether a 
similar weak positive signal was captured there.   
What do the results mean for other A antibody approaches?  The next up is 
aducanumab.  This targets plaque rather than soluble A and has been shown to 
remove plaques in imaging studies (Sevigny et al. 2016).  This is indeed an 
interesting approach.  However, although there is a sense of optimism about this, 
a potential concern is that bapineuzumab also partially cleared plaques, albeit in 
the context of amyloid-related imaging abnormalities, without evidence for 
clinical utility (Holmes et al. 2008).  This imperfect precedent argues that simple 
clearance is not the answer.  Also, much has been made of the correlation 
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between plaque reduction and improved cognitive function in this trial, but this 
is a little puzzling because it is well established that plaque load does not 
correlate with cognitive performance during disease development so it is 
surprising that it should correlate with plaque removal.  We should be cautious 
about repeating our excitement over Phase 1 trial data. 
What does this mean for therapeutic approaches targeting earlier stages of the 
A cascade, particularly BACE inhibition?  BACE inhibitors have the considerable 
advantage over antibodies in being relatively inexpensive and in having clear 
and simple endpoints.  Human genetic data suggests that life-long BACE 
inhibition should protect against the disease (Jonsson et al. 2012), although this 
hypothesis needs further confirmation both at the functional and the genetic 
level (De Strooper and Voet 2012).  The crucial question, then, is at what stage 
would BACE inhibition have clinical efficacy?  Even at the stage of early clinical 
disease, the disease process is fairly advanced and plaque load is near saturation.  
The verubescestat data, optimistically interpreted, suggest that at this stage 
reduction of A production comes too late, but that, taking the trigger hypothesis 
into account, an earlier intervention could still be effective.  While the ethical and 
practical difficulties of preclinical treatment are clear, they are not insuperable, 
even in “sporadic” disease (Escott-Price et al 2015). 
What about other therapeutic approaches?  The amyloid hypothesis has ruled 
supreme for 25 years, but the Jack curves make clear the long period from 
amyloid deposition to clinical symptoms. The clinical data suggest that the linear 
relationship between Aβ and dementia is not tenable. Instead, during this long 
prodromal period (the cellular phase: De Strooper and Karran 2016), many 
other processes are under way, These include the microglial response to amyloid 
deposition and, at least partly independently of amyloid deposition, tau 
pathology spread (Walker et al. 2013).  These processes are now in the spot light 
and it will become hard to obtain further investments in anti-amyloid therapies 
unless the ongoing trials in preclinical AD show a positive signal.  
Four final points are worth making.  First, while it has been fashionable to argue 
that transgenic mouse work has misled the field, a close analysis in fact reveals 
that the animal data have been accurate in predicting the outcome of treatment 
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strategies: Solanuzumab did not clear established plaques in the clinical trial and 
it did not do so in transgenic mice either.  BACE inhibitors had been shown to 
slow plaque development but had not been shown to clear existing plaques 
(Hyde et al. 2012).  Second, the simple idea expressed as “amyloid loads the gun 
and tau pulls the trigger” is unsustainable (Karran et al. 2011). It is difficult to 
imagine how, in the initial phases of the disease, A and tau would interact 
biochemically, and subsequently become independent from each other (Small 
and Duff 2008).  Rather, one should think of A pathology, once established, as 
pushing tau pathology indirectly, for instance by altering synaptic activity.  
Third, it might be interesting, considering the threshold hypothesis, to think 
about combination therapies, with BACE inhibitors blocking the generation of Aβ 
and antibodies like aducanuzumab to clear existing Aβ plaques.  Fourth, with the 
solanezumab trial and the release of the data, Eli Lilly have done the field an 
enormous service and this has to be the model for future trials.  Merck will 
hopefully do the same in the near future for the verubecestat data. 
Systematic and open data analysis at all stages of disease investigation will be 
key if we want to make progress. Failed trials have value as long as they are 
taken as lessons to learn from and to improve our concepts and theories.  
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